Madison Asset Management LLC Decreases Holdings in Elevance Health, Inc. $ELV

Madison Asset Management LLC lessened its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 88.4% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 16,600 shares of the company’s stock after selling 126,753 shares during the period. Madison Asset Management LLC’s holdings in Elevance Health were worth $5,364,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Nilsine Partners LLC lifted its holdings in Elevance Health by 1.5% in the third quarter. Nilsine Partners LLC now owns 1,918 shares of the company’s stock valued at $620,000 after acquiring an additional 29 shares during the last quarter. HBK Sorce Advisory LLC raised its position in Elevance Health by 4.4% in the third quarter. HBK Sorce Advisory LLC now owns 743 shares of the company’s stock valued at $260,000 after purchasing an additional 31 shares during the period. Detalus Advisors LLC lifted its stake in shares of Elevance Health by 1.8% in the 3rd quarter. Detalus Advisors LLC now owns 1,726 shares of the company’s stock valued at $558,000 after purchasing an additional 31 shares during the last quarter. Forum Financial Management LP grew its holdings in shares of Elevance Health by 1.1% during the 3rd quarter. Forum Financial Management LP now owns 2,971 shares of the company’s stock worth $960,000 after purchasing an additional 33 shares during the period. Finally, Activest Wealth Management grew its holdings in shares of Elevance Health by 66.7% during the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after purchasing an additional 34 shares during the period. 89.24% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ELV has been the topic of a number of recent analyst reports. Robert W. Baird upped their target price on shares of Elevance Health from $297.00 to $340.00 and gave the company a “neutral” rating in a research report on Thursday, December 11th. Wolfe Research set a $425.00 price target on Elevance Health and gave the stock an “outperform” rating in a research report on Thursday, January 8th. Sanford C. Bernstein cut their price objective on Elevance Health from $431.00 to $409.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Truist Financial decreased their target price on Elevance Health from $400.00 to $390.00 and set a “buy” rating on the stock in a research note on Monday, February 2nd. Finally, UBS Group set a $400.00 target price on Elevance Health in a research report on Thursday, January 29th. Twelve investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $390.55.

Elevance Health Stock Performance

Shares of NYSE ELV opened at $330.07 on Thursday. Elevance Health, Inc. has a one year low of $273.71 and a one year high of $458.75. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.56. The firm has a market cap of $72.85 billion, a price-to-earnings ratio of 13.14, a P/E/G ratio of 1.81 and a beta of 0.50. The stock’s fifty day moving average price is $351.84 and its two-hundred day moving average price is $331.27.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The firm had revenue of $49.31 billion during the quarter, compared to the consensus estimate of $49.52 billion. During the same period in the prior year, the company posted $3.84 EPS. The company’s revenue was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, equities analysts forecast that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be issued a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend is Tuesday, March 10th. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s payout ratio is currently 27.23%.

Key Headlines Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks raised its Q4 2027 EPS estimate sharply to $4.75 from $3.48, signaling higher expected profitability for that quarter (Zacks retains a “Hold” rating).
• Positive Sentiment: Zacks also increased its Q3 2027 EPS view to $6.01 from $5.80, a modest upward revision for that quarter.
• Neutral Sentiment: Zacks trimmed Q4 2026 by a penny (to $3.43 from $3.44), a negligible change unlikely to move the share price materially.
• Neutral Sentiment: Market commentary is re‑examining ELV’s valuation — pieces weighing valuation vs. growth can be neutral unless they prompt revisions to investor positioning. Is Elevance Health (ELV) trading at an attractive valuation?
• Negative Sentiment: Zacks cut multiple near‑term quarterly estimates: Q1 2026 down to $10.40 (from $11.38), Q2 2026 down to $6.30 (from $8.51), and Q1 2027 down to $10.45 (from $13.30). These downgrades lower short‑term earnings visibility and may pressure the stock.
• Negative Sentiment: Zacks reduced full‑year forecasts: FY2026 to $25.53 (from $29.01) and FY2027 to $28.40 (from $31.89), which implies a weaker multi‑year earnings trajectory than previously expected. Zacks maintains a “Hold” rating.
• Negative Sentiment: Regulatory/legal risk has stepped into focus — a House Judiciary probe is examining aspects of Elevance’s valuation and business practices, introducing potential headline risk and uncertainty for investors. House Judiciary Probe Puts Focus On Elevance Health Valuation And Risks

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.